Comparing antimalarial drugs and their effects over the Plasmodium lifecycle

In this week's PLoS Medicine, Michael Delves of Imperial College London, UK and colleagues compare the activity of 50 current and experimental antimalarials against liver, sexual blood, and mosquito stages of selected human and nonhuman parasite species, including Plasmodium falciparum, Plasmodium berghei, and Plasmodium yoelii.

These results provide a valuable guide to help researchers decide which drugs and compounds show most promise as potential future for blocking the transmission of malaria.

The authors say: "This information might guide decisions regarding which molecules could be optimally combined to provide the next generation of drugs that will succeed to artemisinin combination therapies (ACTs) and support the eradication of malaria. This comprehensive approach to drug discovery has potential utility for targeting other pathogens with complex life cycles."

More information: Delves M, Plouffe D, Scheurer C, Meister S, Wittlin S, et al. (2012) The Activities of Current Antimalarial Drugs on the Life Cycle Stages of Plasmodium Life Cycle: A Comparative Study with Human and Rodent Parasites. PLoS Med 9(2): e1001169. doi:10.1371/journal.pmed.1001169

Related Stories

Recommended for you

Time to move Lyme Disease Awareness Month to April?

date 6 hours ago

The month of May brings many things, among them Mother's Day, tulips, and Lyme Disease Awareness campaigns. But according to Dr. Richard S. Ostfeld, a disease ecologist at the Cary Institute of Ecosystem ...

An explanation of wild birds' role in avian flu outbreak

date 8 hours ago

Wild birds are believed to be behind the first major widespread outbreak of bird flu in the United States. The H5N2 virus has cost Midwestern turkey and chicken producers almost 13 million birds since early March, including ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.